

Authorization Page
Generated on December 17, 2015 8:25AM
PERMANENT ADMINISTRATIVE RULES

Oregon Health Authority, Division of Medical Assistance
Programs

410

Agency and Division

Administrative Rules Chapter Number

Sandy Cafourek

dmap.rules@state.or.us

Rules Coordinator

Email Address

500 Summer St. NE, Salem, OR 97301

503-945-6430

Address

Telephone

Upon filing.

Adopted on

12/27/2015

Effective date

RULE CAPTION

PDL March26, May28, July 30, 2015 DUR/P&T Action; Align with Statute for
Brandname Drug Reimbursement

Not more than 15 words

RULEMAKING ACTION

ADOPT:

AMEND: 410-121-0030

REPEAL: 410-121-0030 (T)

RENUMBER:

AMEND & RENUMBER:

Stat. Auth.: ORS 413.032, 413.042, 414.065, 414.325, 414.330 to 414.414, 414.312, and 414.316

Other Auth.:

Stats. Implemented: ORS 414.065; 414.325, 414.334, 414.361, 414.369, 414.371, 414.353, and
414.354

RULE SUMMARY

Aligns rule with ORS 414.325 to allow the Division to limit reimbursement to a
brand name version of a covered drug when its cost is equal to or less than the

cost of the generic version after receiving discounted prices and rebates.

The Pharmaceutical Services Program administrative rules (Division 121) govern Division payments for services provided to certain clients. The Division needs to amend rules as follows:

410-121-0030:

Preferred:

Viekiera Pakâ,,ç

Laxative drug class

Polyethylene glycol 3350

Lactulose

Senna products

Bulk forming laxatives less than \$1/unit

Osmotic laxatives less than \$1/unit

Surfactant, stimulant, and saline laxatives

Isosorbide dinitrate - capsule ER

Nitroglycerin - capsule ER

Adalimumab (Humira Pediatric Crohn'sâ,,ç)

Calcium Citrate - tablet

Buprenorphine HCL / Naloxone HCL

Dexmethylphenidate HCL

Chlorpromazine HCL

Fluphenazine HCL

Dabigatran

Rivaroxaban

Apixaban

Edoxaban

Linezolid

Tobramycin (Tobi Poldhalerâ,,ç)

Tobramycin / Nebulizer (Kitabis â,,ç Pak)

All rectal subclass products

All acetaminophen with codeine products

Ibuprofen containing products

Hydrocodone APAP solution

Metoprolol Succinate

Cilostazol

Fluticasone Propionate

Amlodipine-Olmesartan

Enalapril-Hydrochlorothiazide

Lisinopril-Hydrochlorothiazide

Losartan-Hydrochlorothiazide

Metoprolol Succinate-Hydrochlorothiazide

Olmesartan-Amlodipine-Hydrochlorothiazide

Olmesartan-Hydrochlorothiazide


Propranolol-Hydrochlorothiazide

Non-Preferred:

Bulk forming laxatives \$1/unit or more
Osmotic laxatives \$1/unit or more
Lubricant laxatives
Cimetidine - tablet
Spinosad

Semprivir Sodium
Tedizolid Phosphate
Ivacaftor (Kalydeco[®])
All Butalbital subclass products

Pirfenidone
Nintedanib Esylate
All other agents in Intranasal Allergy
Ketoconazole
All other products in Combination Antihypertensives class



Rhonda Busch

12-21-15

Authorized Signer

Printed Name

Date

Authorization Page replaces the ink signature on paper filings. Have your authorized signer sign and date, then scan and attach it to your filing. You must complete this step before submitting your Permanent and Temporary filings.

410-121-0030

Practitioner-Managed Prescription Drug Plan

(1) The Practitioner-Managed Prescription Drug Plan (PMPDP) is a plan that ensures that OHP fee-for-service clients have access to the most effective prescription drugs appropriate for their clinical conditions at the best possible price:

(a) Licensed health care practitioners, who are informed by the latest peer reviewed research, make decisions concerning the clinical effectiveness of the prescription drugs;

(b) Licensed health care practitioners also consider the client's health condition, personal characteristics, and the client's gender, race, or ethnicity.

(2) PMPDP Preferred Drug List (PDL):

(a) The PDL is the primary tool the Division uses to inform licensed health care practitioners about the results of the latest peer-reviewed research and cost effectiveness of prescription drugs;

(b) The PDL contains a list of prescription drugs that the Division, in consultation with the Drug Use Review (DUR)/Pharmacy & Therapeutics Committee (P&T), has determined represent the most effective drugs available at the best possible price;

(c) The PDL shall include drugs that are Medicaid reimbursable and the Food and Drug Administration (FDA) has determined to be safe and effective.

(3) PMPDP PDL Selection Process:

(a) The Division shall utilize the recommendations made by the P&T that result from an evidence-based evaluation process as the basis for selecting the most effective drugs;

(b) The Division shall ensure the drugs selected in section (3)(a) that are available for the best possible price and shall consider any input from the P&T about other FDA-approved drugs in the same class that are available for a lesser relative price. The Division shall determine relative price using the methodology described in section (4);

(c) The Division shall evaluate selected drugs for the drug classes periodically:

(A) The Division may evaluate more frequently if new safety information or the release of new drugs in a class or other information makes an evaluation advisable;

(B) New drugs in classes already evaluated for the PDL shall be non-preferred until the new drug has been reviewed by the P&T;

(C) The Division shall make all revisions to the PDL using the rulemaking process and shall publish the changes on the Division's Pharmaceutical Services provider rules website.

(4) Relative cost and best possible price determination:

(a) The Division shall determine the relative cost of all drugs in each selected class that are Medicaid reimbursable and that the FDA has determined to be safe and effective;

(b) The Division may also consider dosing issues, patterns of use, and compliance issues. The Division shall weigh these factors with any advice provided by the P&T in reaching a final decision.

(5) Pharmacy providers shall dispense prescriptions in the generic form unless:

(a) The practitioner requests otherwise pursuant to OAR 410-121-0155;

(b) The Division notifies the pharmacy that the cost of the brand name particular drug, after receiving discounted prices and rebates, is equal to or less than the cost of the generic version of the drug.

(6) The exception process for obtaining non-preferred physical health drugs that are not on the PDL drugs shall be as follows:

(a) If the prescribing practitioner in their professional judgment wishes to prescribe a physical health drug not on the PDL, they may request an exception subject to the requirements of OAR 410-121-0040;

(b) The prescribing practitioner must request an exception for physical health drugs not listed in the PDL subject to the requirements of OAR 410-121-0060;

(c) Exceptions shall be granted when:

(A) The prescriber in their professional judgment determines the non-preferred drug is medically appropriate after consulting with the Division or the Oregon Pharmacy Call Center; or

(B) Where the prescriber requests an exception subject to the requirement of section (6)(b) and fails to receive a report of PA status within 24 hours, subject to OAR 410-121-0060.

(7) Table 121-0030-1, PMPDP PDL dated November 1, 2015 is adopted and incorporated by reference and is found at: www.orpdl.org.

Stat. Auth.: ORS 413.032, 413.042, 414.065, 414.325, 414.330 to 414.414, 414.312, 414.316

Stats. Implemented: ORS 414.065; 414.325, 414.334, 414.361, 414.369, 414.371,
414.353, 414.354